Bringing the very best science and medicine to our best equine friends
Events

Kindred Biosciences Receives Approval of Effectiveness Technical Section from FDA for Zimeta New Animal Drug Application

San Francisco, CA (October 4, 2016) Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced it has received a technical section complete letter for effectiveness from the U.S. Food and Drug Administration’s Center for Veterinary Medicine for Zimeta™ (dipyrone injection) approving the technical section. The basis for this complete letter was a multicenter, randomized, blinded, placebo-controlled pivotal study that enrolled 138 horses to assess the effectiveness of Zimeta. The primary endpoint was improvement (a 2°F or greater decrease in temperature from baseline) or resolution of fever (a return to normothermia …

Continue Reading

QH Kids in STEM Sign-Up Opens

QH Kids in STEM Sign-Up Opens Sponsored by Kindred Biosciences to encourage youth from quarter horse backgrounds to study and pursue careers in science, technology, engineering and mathematics. Indianola, IA: The GoodRide Group STEM Alliance and Kindred Biosciences (NASDAQ: KIN) are excited to announce that youth and parents from around the country can sign up to participate at no cost in QH Kids in STEM. “Inspire and engage is the goal for QH Kids in STEM digital series as the demand for skilled workers in science, technology, engineering and mathematics continues to rise,” cited Kris Moorman, founder of The GoodRide …

Continue Reading

Kindred Biosciences Corporate Update via Webcast in Advance of One-on-One Investor Meetings in San Francisco January 12-14, 2016.

Monday, January 11, 2016 Time of Event: 8:30 AM Eastern Standard Time Webcast URL: http://edge.media-server.com/m/p/sfos7gz9  For more information on this event, please see the press release

Continue Reading

Kindred Biosciences to Provide Corporate Update via Webcast in Advance of One-on-One Investor Meetings in San Francisco January 12-14, 2016.

San Francisco, CA (January 7, 2016) Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it will provide a corporate update via webcast on Monday, January 11, 2016 in advance of one-on-one investor meetings in San Francisco January 12-14, 2016.

Continue Reading

Kindred Biosciences Announces Positive Results from Pivotal Study of KIND-012 for Pyrexia in Horses, and Provides Other Product Updates

KIND-012 study meets primary endpoint with p<0.0001. Data to be filed with the FDA for approval. SentiKind study misses primary endpoint. Conference call and webcast scheduled for 5:00 p.m. Eastern Time today. San Francisco, CA (November 16, 2015) Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced positive topline results from its pivotal field study (KB0120) of KIND-012 for the control of pyrexia (fever) in horses.

Continue Reading

KindredBio to Announce Fourth Quarter and Year-End 2014 Financial Results

Company to Hold Conference Call and Webcast at 4:30 p.m. Eastern Time on Thursday, March 12, 2015 SAN FRANCISCO, California. (March 3, 2015) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, announced today that it will release its fourth quarter and year-end 2014 financial results on March 12, 2015 after the market close. The Company will host a conference call at 4:30 p.m. Eastern Time that day.

Continue Reading